Nabeel Aslam, MD
Nephrology · Jacksonville, FLNPI 1174579148
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $3,600 of the $5,992 with a category attached, or 60.1%. Travere Therapeutics, Inc. accounts for 65.0% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2022 at $3,892 and has fallen 100.0% since, to $0 in 2025.
Across 15 payments — averaging $399.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Travere Therapeutics, Inc.$4K
- Amgen$1K
- Boehringer Ingelheim International GmbH$878
- Genentech, Inc.$111
- Baxter Healthcare$74
Across 49 payments — averaging $7809.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$209K
- AstraZeneca$73K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$57K
- Baxter Healthcare$25K
- Boehringer Ingelheim International GmbH$18K
What the payments were for
- Consulting fees$1,00017%
- Speaking & faculty fees$3,60060%
- Travel & lodging$89515%
- Food & beverage$4978%
- Education$00%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Travere Therapeutics, Inc. | 6 | $3,892 |
| Amgen | 2 | $1,037 |
| Boehringer Ingelheim International GmbH | 5 | $878 |
| Genentech, Inc. | 1 | $111 |
| Baxter Healthcare | 1 | $74 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,992 in reported general payments places this provider in the 80th percentile of 756 nephrology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 11 | $11,912 |
| Dexlansoprazole DrDexlansoprazole | 13 | $1,400 |
| Nifedipine ErNifedipine | 16 | $550 |
| Losartan Potassium | 39 | $460 |
| Metoprolol Succinate | 19 | $284 |
| Atorvastatin Calcium | 31 | $252 |
| Amlodipine Besylate | 20 | $184 |
| Valsartan | 14 | $173 |
| Potassium Chloride | 12 | $158 |
| Famotidine | 12 | $146 |
| Allopurinol | 13 | $141 |
| Torsemide | 11 | $137 |
| Spironolactone | 12 | $100 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Jacksonville
- Fouad ChebibJacksonville$122K
- Jeremy CarlsonJacksonville$105K
- Craig ShapiroJacksonville$57K
- Hani WadeiJacksonville$53K
- Deborah PriceJacksonville$15K
- Tambi JarmiJacksonville$12K
- Arvind MadanOrlando$943K
- John CopleyWeston$934K
- Jorge LarranagaKissimmee$825K
- Carlos BejarFort Lauderdale$530K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.